Source: CureToday articles
The phase 3 POIESIS trial is set to investigate navtemadlin as an add-on therapy to Jakafi in patients with JAK inhibitor-naive myelofibrosis.
Recent Content
- Rite Aid Intends to File Second Bankruptcy, Raising Questions About Its Future
- A Staunch Advocate For Radiation Oncology Nursing and Compassionate Care
- A Personalized Approach to Bladder Preservation in Urologic Cancers
- GPRC5D-Targeted CAR T-Cell Therapy Shows Promise After BCMA Treatment Failure
- Novel HER2-low Therapies and Pharmacist-Led ADC Sequencing
- Mitigating Peripheral Neuropathy During Cancer Treatment
- POIESIS Trial Explores Navtemadlin Plus Jakafi for Myelofibrosis
- My Lung Cancer Journey: With Family, Friends and Medical Professionals
- The Impact of Respiratory Syncytial Virus (RSV) on Vulnerable Populations
- Identifying Candidates for RSV Vaccination